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ABSTRACT
Patients with cancer are at high risk to develop venous
thromboembolism, and they are also more likely to
develop complications from anticoagulant treatment.
Because little research has focused on the oncology
population to date, the optimal methods of prophy-
laxis and treatment remain uncertain in some clinical
situations. Currently, low molecular weight heparin
and warfarin are the most frequently used pharma-
cologic agents; however, they have their limitations.
Other therapeutic options, such as inferior caval fil-
ters, are poorly studied and remain controversial. A
summary of the most recent evidence on the preven-
tion and treatment of venous thromboembolism in
cancer patients is presented here.
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1. INTRODUCTION
It is well established that cancer patients are at an in-
creased risk of venous thromboembolism (VTE). In fact,
the presence of malignancy increases the risk of VTE
by a factor of 4 to 6, and large population-based stud-
ies show that the incidence of VTE is on the rise 1,2.
Overall, cancer patients constitute 15%–20% of the
patients diagnosed with VTE, and depending on the type
of tumour, extent of malignancy, type of cancer treat-
ment, and presence of other risk factors, 1%–25% of
patients with malignancy will develop thrombosis.
Furthermore, cancer-associated thrombosis is linked
with poor prognosis, and it is the second leading cause
of death in cancer patients 3. In one study of a popula-
tion registry, the 1-year survival of cancer patients di-
agnosed with VTE was one third that of cancer patients
without VTE (12% vs. 36%) matched for sex, age, tu-
mour type, and duration of the cancer 4. In another popu-
lation-based study, the in-hospital mortality for cancer
patients who developed VTE while in hospital was double
that for patients who did not develop the complication 5.
This increase in mortality is partly attributable to fatal
pulmonary embolism, but it also reflects the advanced
stages of cancer and underlying aggressive tumour bi-
ology in these patients.
Cancer patients are also prone to adverse effects
and failure of anticoagulant therapy. In comparison
with patients without cancer, patients with cancer who
are receiving warfarin experience 2 to 6 times more
major bleeding episodes and 2 to 3 times more VTE
recurrences 6,7. Based on prospective studies, the an-
nual risk of recurrent VTE is 21%–27% and the an-
nual risk of major bleeding is 12%–13%.
Primary prevention is the most effective way to
reduce the morbidity and mortality associated with
cancer-associated thrombosis, but surveys and regis-
tries consistently report the failure of physicians to
comply with established guidelines leading to
underutilization of primary prophylaxis in oncology
patients 8. Given the impact that VTE has on this high-
risk population, an increased focus on identifying op-
timal methods to prevent and treat VTE in patients with
malignancy is needed. Current management strategies,
and the evidence supporting them, are presented here.
2. PRIMARY PREVENTION: SURGICAL
SETTINGS
The risk of VTE in cancer patients undergoing surgery
has been estimated to be as high as 50% without pro-
phylaxis 9. The exact risk varies with the type of sur-
gery, but anticoagulants are generally effective in
reducing the risk by 50%–80%. Tables I to III summa-
rize the results from randomized controlled trials
evaluating the efficacy and safety of anticoagulant
prophylaxis in various oncologic surgery settings 10–23.
2.1 Major Abdominal and Pelvic Surgery
After major abdominal or pelvic cancer surgery, phar-
macologic intervention with anticoagulants for 7–
14 days postoperatively can reduce the risk of VTE to
1.3% for symptomatic deep vein thrombosis (DVT) and
0.4% for fatal pulmonary embolism. However, these
numbers still represent a doubling or tripling of the risk
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TABLE I Randomized controlled trials for primary prophylaxis in cancer-related major abdominal and pelvic surgery
Trial Surgical Cancer Regimen Duration Outcome Incidences
setting patients Study Control of VTE Major bleeding
(n) treatment Study Control p Value Study Control p Value
(%) (%) (%) (%)
Enoxacan Study Group, Abdominal 631 Enoxaparin UFH 5000 IU 10 Days VTE on bilateral venography 14.7 18.2 >0.05 4.1 2.9 >0.05
1997 10 and pelvic 40 mg daily 3 times daily or pulmonary scintigraphy
McLeod et al., Colorectal 324 Enoxaparin UFH 5000 IU Up to PE, venographic DVT 13.9 16.9 0.052 2.7a 1.5a 0.136a
2001 11 40 mg daily 3 times daily 10 days at postoperative days 5, 9
Agnelli et al., Major 1941 Fondaparinux Dalteparin 5–9 Days Venographic DVT or PE 4.7 7.7 <0.05 3.4 2.5 0.355
2005 12 abdominal 2.5 mg daily 5000 IU daily up to postoperative day 10
Bergqvist et al., Abdominal 332 Enoxaparin Enoxaparin 27–31 Days Bilateral venography 4.8 12.0 0.02 0.4 0 >0.99
2002 13 and pelvic 40 mg daily 40 mg daily (study) between days 25 and 31
6–10 Days
(control)
Rasmussen et al., Major 198 Dalteparin Dalteparin 28 Days Venographic VTE on 8.8 19.6 0.03 0.5a 1.8a >0.05a
2006 14 abdominal 5000 IU daily 5000 IU daily (study) postoperative days 7–28
7 Days
(control)
a Results for the overall study population, including cancer and noncancer patients.
VTE = venous thromboembolism; UFH = unfractionated heparin; PE = pulmonary embolism; DVT = deep vein thrombosis.
TABLE II Randomized controlled trials for primary prophylaxis in cancer-related neurosurgery
Trial Surgical Patients Regimen Duration Outcome Incidences
setting (n) Study Control of VTE Major bleeding
treatment Study Control p Value Study Control p Value
(%) (%) (%) (%)
Nurmohamed et al., Craniotomy or 485 Nadroparin Placebo 10 Days Venographic 18.7 26.3 0.047 2.50 0.80 0.87
1996 15 spinal surgery 7500 IU daily and GCS or until DVT at day 10
for tumour and GCS discharge
or injury
Agnelli et al., Elective cranial or 307 Enoxaparin Placebo At least Venographic 17 33 0.004 3 3 >0.05
1998 16 spinal surgery 40 mg daily and GCS 7 days DVT at day 8,
for tumours and GCS or PE
Goldhaber et al., Craniotomy 150 Enoxaparin UFH 5000 IU Until VTE Ultrasonographic 12 6.7 0.401 2.7 1.3 >0.05
2002 17 for brain tumour 40 mg daily twice daily or discharge DVT at discharge
and GCS and IPC and GCS and IPC
Macdonald et al., Craniotomy 100 Dalteparin UFH 5000 IU 7 Days, PE, or 4 0 >0.05 4 2 >0.05
2003 18 2500 IU daily twice daily or until ultrasonographic
and IPC and IPC ambulating DVT at 1 month
VTE = venous thromboembolism; GCS = graduated compression stockings; DVT = deep vein thrombosis; PE = pulmonary embolism; IPC = intermittent pneumatic compression; UFH =
unfractionated heparin.C
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TABLE III Randomized controlled trials for primary prophylaxis in cancer-related gynecologic surgery
Trial Patients Regimen Duration Outcome Incidences
(n) Study Control of VTE Major bleeding
treatment Study Control p Value Study Control p Value
(%) (%) (%) (%)
Heilmann et al., 300 LMWH UFH 5000 IU 7 Days PE, DVT by 1.3 4.0 >0.05 No significant difference in
1989 19 1500 IU daily 3 times daily impedance clinical and laboratory measures,
plethysmography specific incidence of major
to day 7 bleeding not cited
Clarke–Pearson et al., 200 UFH 5000 IU No Until PE, DVT by 6.2 18.4 0.008 No significant difference in
1990 20 every 8 hours prophylaxis discharge 125I-labelled fibrinogen clinical and laboratory measures,
pre- and  scan, impedance specific incidence of major
postoperatively plethysmography bleeding not cited
to day 30
Fricker et al., 80 Dalteparin 2500 IU UFH 5000 IU 10 Days PE, DVT by 0 2.5 >0.05 5.1 2.5 >0.05
1988 21 2 hours 2 hours 125I-labelled fibrinogen
preoperatively preoperatively, scan, venography
and at 12 hours, then to 4 weeks
then 5000 IU daily 3 times daily
Von Tempelhoff et al.,6 0 LMWH UFH 7 Days PE on scintigraphy, 6.7 0 >0.05 Not assessed
1997 22 3000 IU daily 5000 IU DVT by impedance
3 times daily plethysmography,
venography,
up to day 30
Heilmann et al., 324 Certoparin UFH 7 Days DVT by impedance 6.3 6.1 1.0 16.8 28.7 0.01
1998 23 3000 IU daily 5000 IU plethysmography,
3 times daily  venography
up to day 10
VTE = venous thromboembolism; LMWH = low molecular weight heparin; UFH = unfractionated heparin; PE = pulmonary embolism; DVT = deep vein thrombosis.BROSE and LEE
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as compared with patients without malignancy 24,25. Of
the agents available for thromboprophylaxis, low mo-
lecular weight heparins (LMWHs) provide the most con-
venient, efficacious, and safe option (Table I) 10–14,26.
Compared with LMWHs, unfractionated heparin requires
3-times-daily injection and has a higher risk of hepa-
rin-induced thrombocytopenia. And although
fondaparinux appears to be comparable to LMWH in ef-
ficacy and safety, limited data are available for it in the
cancer setting, and a specific antidote for it is lacking.
A post hoc subgroup analysis of cancer patients in a
randomized trial found a lower risk of VTE with
fondaparinux than with dalteparin, but that finding re-
quires confirmation in future studies 12.
However, as hospital stays have shortened, the
duration of prophylaxis may be inadequate for some
patients. Cancer patients are at particularly high risk,
considering that many of them undergo extensive sur-
gery and require prolonged periods of recovery. In a
prospective cohort study in which 2373 cancer pa-
tients were followed for a minimum of 30 days after
surgery, 40% of symptomatic VTE occurred more than
3 weeks postoperatively, and 46% of deaths were the
result of fatal pulmonary embolism 27. Clinical fac-
tors found to be associated with a higher risk of VTE
were previous history of VTE [odds ratio (OR): 6.0],
anaesthesia lasting 2 hours or longer (OR: 4.5), bed
rest for 4 days or longer (OR: 4.4), an advanced stage
of cancer (OR: 2.7), and age 60 years or older (OR: 2.6).
Randomized controlled trials have shown that con-
tinuing prophylaxis with a LMWH up to 30 days post-
operatively can reduce the risk of VTE by 60% without
increasing the risk of bleeding (Table I) 13,14. Based
on these and other supportive studies, it is reasonable
to prescribe extended prophylaxis in patients with one
or more risk factors for VTE.
2.2 Neurosurgery
Neurosurgical patients present a challenging prophy-
laxis problem because of the underlying concern of in-
tracerebral hemorrhage combined with a high incidence
of VTE. In fact, craniotomy for brain neoplasm carries a
VTE risk of 60% in the postoperative period and 23% at
1 year 28. This risk can be reduced by 40% with the use
of LMWH prophylaxis starting 24 hours postoperatively
(Table II) 15–18. The risk of major bleeding, including
intracranial hemorrhage, is less than 3%, but that risk
is increased if LMWH prophylaxis is administered pre-
operatively 29. However, given the devastating conse-
quences of an intracranial hemorrhage, most
neurosurgeons prefer to use mechanical compression
devices in the early operative period and to start phar-
macologic prophylaxis when patients are more stable.
2.4 Gynecologic Surgery
Compared with the previous two groups, women un-
dergoing gynecologic cancer surgery have a lower
risk of VTE—about 2%. But that level of risk repre-
sents an increase by a factor of 5 over the risk in
women having surgery for benign gynecologic prob-
lems 9. As with abdominal and pelvic surgery,
unfractionated heparin and LMWH are both equally ef-
fective and safe in preventing DVT in this setting
(Table III) 19–23,30. Mechanical devices have also been
shown to be effective.
2.5 Other Surgeries
There is a paucity of research on the risk of VTE and
on its prevention in other surgical settings. Based on
limited data and extrapolation from other surgical
groups, unfractionated heparin and LMWH both ap-
pear relatively safe and effective, but solid evidence
is lacking.
2.6 Mechanical Prophylaxis in Surgical Settings
As shown in one meta-analysis 31, compression stock-
ings are effective in reducing the risk of VTE by two
thirds in patients at moderate risk. Pneumatic com-
pression devices are also effective, but they are cum-
bersome and interfere with mobilization. Also, they
are more likely than pharmacologic prophylaxis to
fail in high-risk groups 32. Compression devices are
therefore currently reserved for situations in which
anticoagulation is contraindicated. These devices are
most effective when applied intraoperatively or im-
mediately after surgery (Table IV) 33–35. Whether me-
chanical methods in combination with anticoagulants
result in additional risk reduction is not clear.
2.7 Summary: Surgical Settings
Good evidence supports the routine use of postopera-
tive thromboprophylaxis in patients undergoing sur-
gery for cancer (Tables I to IV). That finding is endorsed
by international and national consensus guidelines,
including those from the American College of Chest
Physicians (ACCP) 9, the American Society of Clinical
Oncology (ASCO) 36, and the Italian Association of
Medical Oncology (AIOM) 37. Unfractionated heparin
and LMWH are equally effective in preventing VTE and
have a comparable risk for bleeding. Less experience
and data are available for fondaparinux. Extended pro-
phylaxis should be strongly considered in patients with
additional risk factors for VTE. In those patients who
have a contraindication for anticoagulation, mechani-
cal methods are reasonable substitutes.
3. PRIMARY PREVENTION: MEDICAL
SETTINGS
3.1 Ambulatory Patients
The risk of symptomatic VTE in the ambulatory out-
patient setting is lower than that in the surgical setting,CANCER-ASSOCIATED THROMBOSIS
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and little research had been done to investigate the
role of anticoagulant prophylaxis. More recently,
three separate randomized controlled trials have
evaluated LMWH prophylaxis in patients with meta-
static breast cancer, non-small-cell lung cancer, and
grades III and IV malignant glioma (Table V) 38–40. No
significant difference in VTE or major bleeding was
observed between the groups receiving LMWH and
placebo. Consequently, routine prophylaxis is not
recommended in ambulatory patients. Notably, the
risk of VTE and major bleeding appear to vary con-
siderably, depending on the type of tumour.
On the other hand, as many as 20%–30% of pa-
tients receiving thalidomide in combination with che-
motherapy or high-dose corticosteroids for treatment
of multiple myeloma will develop symptomatic
VTE 41,42. Although many studies have reported the
use of warfarin, aspirin, or LMWH, insufficient reli-
able data are available to support the efficacy and
safety of these agents. Whether lenalidomide is also
associated with a high risk of VTE is uncertain. Pa-
tients receiving vascular endothelial growth factor
inhibitors such as bevacizumab also have an increased
risk of arterial and, possibly, venous thrombosis 43,44,
but because of an increased bleeding tendency al-
ready associated with this treatment, anticoagulation
prophylaxis is not recommended.
3.2 Hospitalized Patients
No study has been conducted in cancer patients to
determine the effects of VTE prophylaxis in the inpa-
tient setting. Large randomized trials that included
small numbers of cancer patients have shown that
LMWH or fondaparinux can reduce the VTE risk by 50%
or more, but whether such results can apply to all
hospitalized cancer patients is questionable, because
of the higher risks for VTE and major bleeding in those
patients 45–47.
3.3 Summary: Medical Settings
Based on limited data, routine prophylaxis in the
outpatient setting is not recommended, but prophy-
laxis should be considered in patients receiving tha-
lidomide- or lenalidomide-containing regimens.
Anticoagulant prophylaxis for hospitalized patients
is warranted based on studies in non-cancer patients,
but the risk–benefit ratio is uncertain, given the lack
of randomized trial evidence.
4. PROPHYLAXIS FOR CENTRAL VENOUS
CATHETERS
Central venous catheters are frequently placed in can-
cer patients, and those devices represent an ongoing
thrombogenic focus 48. Many attempts have been
made to reduce the incidence of thrombotic compli-
cations in this setting, but randomized placebo-con-
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trolled trials have failed to show a reduction in cath-
eter-related thrombosis with thromboprophylaxis. In
particular, low-dose warfarin 49, adjusted-dose war-
farin 50, and prophylactic-dose LMWH 51,52 do not re-
duce the 4% risk of symptomatic catheter–related
thrombosis (Table VI) 49–52. For that reason and be-
cause of the possibility of increased risk of bleeding,
the routine use of prophylaxis in this setting is not
recommended 9.
5. SECONDARY PREVENTION
5.1 Treatment of VTE
Traditional therapy for acute VTE has consisted of ini-
tial therapy with unfractionated heparin or LMWH, fol-
lowed by long-term warfarin therapy. Unfortunately,
many cancer patients tolerate warfarin poorly, espe-
cially when receiving chemotherapy, with its ensu-
ing gastrointestinal and hematologic side effects.
Also, despite maintenance of therapeutic levels of
warfarin, one third of patients experience recurrent
VTE or treatment-related bleeding 6,7.
However, LMWH is clearly superior to warfarin
with respect to convenience and efficacy. Given as a
once-daily subcutaneous injection, LMWH does not
require routine laboratory monitoring, has few drug
interactions, and does not rely on gastrointestinal
absorption. In the CLOT study, 676 cancer patients with
acute DVT or pulmonary embolism were randomized
to a 6-month course of traditional therapy with
dalteparin followed by warfarin, or to dalteparin
alone 53. To reduce the risk of bleeding in the
dalteparin-only group, the dalteparin dose was re-
duced by 20%–25% after the first month of therapy.
After 6 months of treatment, the long-term dalteparin
group experienced a 52% reduction in symptomatic
recurrent VTE (17% vs. 9%, p = 0.002) as compared
with the group continuing on warfarin. In other words,
1 episode of recurrent VTE was prevented for every
13 patients treated. Furthermore, the groups showed
no significant difference in bleeding (4% vs. 6% re-
spectively) and no difference in overall mortality.
Based on those results and on supportive find-
ings from other trials (Table VII) 53–56, the 2004 ACCP
guidelines 57, the ASCO VTE guidelines 36, and AIOM 37
recommend the use of LMWH alone for treatment of
VTE in most patients with cancer. Currently, only
dalteparin has received regulatory approval for long-
term treatment of symptomatic VTE in patients with
cancer.
5.2 Recurrent VTE
As mentioned earlier, recurrence of VTE is more com-
mon in the setting of warfarin therapy than of LMWH
therapy. Unfortunately, the optimal treatment for such
patients has yet to be determined. Inferior caval fil-
ters have frequently been used in cases of warfarin
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failure, but evidence from a large randomized trial
primarily in patients without cancer showed that, al-
though the risk of short-term pulmonary embolism is
reduced by about three quarters, patients receiving a
filter are about twice as likely to develop recurrent
VTE. Also, no difference in overall survival was
seen 58. Furthermore, because of the increased risk
of recurrent VTE, cancer patients may be at higher risk
for development of postphlebitic syndrome.
Based on the foregoing findings, using caval fil-
ters as treatment for recurrent VTE cannot be recom-
mended. Rather, changing a warfarin regimen to
TABLE VII Randomized controlled trials for treatment of cancer-related venous thromboembolism (VTE)
Trial Patients Regimen Duration Outcome Incidences
(n) Study Control of VTE Major bleeding
treatment Study Control p Value Study Control p Value
(%) (%) (%) (%)
Meyer et al., 146 Enoxaparin Enoxaparin 3 Months Combined 10.5a 21.1a 0.09a 7.0 16.0 0.09
 2002 54 1.5 mg/kg daily 1.5 mg/kg daily recurrent VTE
for 5–7 days, then and
warfarin at INR 2–3 hemorrhage
Lee et al., 672 Dalteparin Dalteparin As described Recurrent VTE 9.0 17.0 0.002 6 4 0.27
2003 53 200 IU/kg daily 200 IU/kg daily in “Regimen”
for 1 month, for 5–7 days,
then 150 IU/kg then warfarin
daily for  at INR 2–3
5 months
Deitcher et al., 122 Enoxaparin Enoxaparin 5 Days Recurrent VTE 6.9 10.00 >0.05 6.5 2.90 >0.05
2006 55 1 mg/kg twice daily, 1 mg/kg twice daily, at twice daily, (1 mg), (1 mg),
then 1.0 mg/kg daily then warfarin then 6 months 6.3 11.1
or 1.5 mg/kg daily  at INR 2–3 (1.5 mg) (1.5 mg)
Hull et al., 200 Tinzaparin UFH infusion 3 Months Recurrent VTE 6.0b 10.0b >0.05b 7.0 7.0 >0.05
2006 56 175 IU/kg daily then warfarin
at INR 2–3
a Combined 3-month incidence of patients with either recurrent venous thromboembolism or major bleeding.
b 3-Month incidence of patients with recurrent venous thromboembolism.
VTE = venous thromboembolism; INR = international normalized ratio.
TABLE VI Randomized controlled trials for primary prophylaxis in central venous catheters in cancer patients
Trial Patients Regimen Duration Outcome Incidences
(n) Study Control of VTE Major bleeding
treatment Study Control p Value Study Control p Value
(%) (%) (%) (%)
Couban et al., 255 Warfarin 1 mg Placebo Until DVT, CVC-associated 4.6 4.0 >0.05 0 2 0.5
2005 49 or until thrombosis
line removed on ultrasound
or venography
Young et al., 1589 Adjusted warfarin Placebo Until DVT, CVC-associated 5 6 0.84 2 0.2 0.07
2005 50 for INR 1.5–2.0 or until thrombosis
or warfarin 1 mg line removed on ultrasound
or venography
Verso et al., 321 Enoxaparin Placebo Until DVT, Venographic DVT, 14.1 18.0 0.35 0 0 >0.05
2005 51 40 mg daily or until or PE
line removed
Karthaus et al., 425 Dalteparin Placebo 12 Weeks PE, 3.7 3.4 0.88 0.004 0 >0.05
2006 52 5000 IU daily venographic or
ultrasono-
graphic DVT
VTE = venous thromboembolism; DVT = deep vein thrombosis; CVC = central venous catheter; INR = international normalized ratio; PE = pul-
monary embolism.BROSE and LEE
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LMWH, or increasing the dose of LMWH would be
appropriate.
5.3 Duration of Therapy
The optimum duration of anticoagulation in patients
with cancer has not been investigated. Extrapolating
from populations without cancer, most patients should
receive a minimum of 3–6 months of therapy. How-
ever, given that cancer represents an ongoing risk fac-
tor in this population, the general recommendation is
to continue anticoagulation for long as evidence of
active malignancy continues. It is of foremost im-
portance that patient care be tailored to suit the indi-
vidual, with due consideration for quality of life and
life expectancy.
5.4 Summary of Secondary Prevention
First-line treatment of VTE in patients with cancer is
LMWH for a minimum of 3–6 months. This approach
is endorsed by the ACCP, ASCO, AIOM, and the National
Comprehensive Cancer Network. The optimum du-
ration is not known, but treatment is usually contin-
ued for as long as evidence of malignancy continues.
6. FUTURE DIRECTIONS
The LMWHs have simplified and improved the pre-
vention and treatment of VTE in patients with cancer.
Much work must still be done to help identify high-
risk patients who would benefit from primary
thromboprophylaxis for extended periods after can-
cer surgery, during medical hospitalization, for pre-
vention of catheter-related thrombosis, and for
prevention of VTE associated with highly thrombo-
genic agents (thalidomide, for example). Also, opti-
mal management in patients with established VTE
should be investigated, especially with regard to du-
ration of therapy and the potential role, if any, of in-
vasive strategies such as filter insertion. Lastly,
education of physicians to improve the appropriate
utilization of prophylaxis in various settings will go
a long way toward reducing morbidity and mortality
in this vulnerable population.
7. SUMMARY
Recommendations for managing risk of thrombotic
events:
• Cancer patients undergoing surgery require VTE
prophylaxis, and this prophylaxis can safely be
extended in high-risk patients after discharge.
• Medical inpatients with cancer should receive VTE
prophylaxis unless absolute contraindications—
active bleeding, for instance—are present.
• Prophylaxis for central venous catheters is not
recommended.
• Prophylaxis in ambulatory patients is not recom-
mended, except in those who are receiving thali-
domide- or lenalidomide-based combination
chemotherapy.
• Venous thromboembolism is best treated with
LMWH for a minimum of 3–6 months, and treat-
ment can be continued for as long as active can-
cer is present.
• Inferior caval filters prevent pulmonary embolism
in the short term, but they carry a long-term risk
of increased VTE and should therefore be avoided
when anticoagulation can be administered.
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